TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PLIAGLIS

LIDOCAINE
Gastroenterology Approved 2006-06-29
1
Indication
--
Phase 3 Trials
19
Years on Market

Details

Status
Prescription
First Approved
2006-06-29
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: LIDOCAINE , TETRACAINE

PLIAGLIS Approval History

Loading approval history...

What PLIAGLIS Treats

6 indications

PLIAGLIS is approved for 6 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
  • Soreness
  • Burning
  • Itching
  • Hemorrhoids
  • Anorectal Discomfort
Source: FDA Label

Drugs Similar to PLIAGLIS

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ORAQIX
LIDOCAINE
6 shared
DENTSPLY PHARM
Shared indications:
PainSorenessBurning +3 more
ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
DILAUDID
HYDROMORPHONE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Pain
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Pain
EC-NAPROSYN
NAPROXEN
1 shared
ATNAHS PHARMA US
Shared indications:
Pain
EXPAREL
BUPIVACAINE
1 shared
PACIRA PHARMS INC
Shared indications:
Pain
FLECTOR
DICLOFENAC EPOLAMINE
1 shared
IBSA
Shared indications:
Pain
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PLIAGLIS FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

For the temporary relief of pain, soreness, and burning. Helps relieve the local itching and discomfort associated with hemorrhoids. Temporarily shrinks hemorrhoidal tissue. Temporarily provides a coating for the relief of anorectal discomforts. Temporarily protects the inflamed, irritated anorectal surface to help make bowel movements less painful.

PLIAGLIS Patents & Exclusivity

Latest Patent: Jan 2031

Patents (3 active)

US10603293 Expires Jan 14, 2031
US10751305 Expires Jan 14, 2031
US10350180 Expires Jan 14, 2031
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.